Phreesia, Inc. (NYSE:PHR) Receives Average Recommendation of “Buy” from Analysts

Phreesia, Inc. (NYSE:PHRGet Rating) has been assigned a consensus recommendation of “Buy” from the seventeen research firms that are currently covering the firm, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $51.06.

A number of equities analysts have weighed in on PHR shares. SVB Leerink reduced their price objective on shares of Phreesia from $41.00 to $29.00 and set a “market perform” rating for the company in a research report on Thursday, March 31st. Raymond James reduced their price objective on shares of Phreesia from $55.00 to $45.00 and set an “outperform” rating for the company in a research report on Friday, April 1st. Needham & Company LLC reduced their price objective on shares of Phreesia from $65.00 to $35.00 and set a “buy” rating for the company in a research report on Thursday, March 31st. Citigroup reduced their price objective on shares of Phreesia from $54.00 to $36.00 and set a “neutral” rating for the company in a research report on Thursday, March 31st. Finally, Piper Sandler reduced their target price on shares of Phreesia from $54.00 to $42.00 in a research report on Monday, April 4th.

PHR opened at $15.82 on Tuesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.65 and a quick ratio of 5.65. The firm has a fifty day moving average price of $25.49 and a 200 day moving average price of $37.55. Phreesia has a 1 year low of $13.19 and a 1 year high of $76.10. The stock has a market cap of $810.62 million, a P/E ratio of -6.79 and a beta of 1.36.

Phreesia (NYSE:PHRGet Rating) last posted its earnings results on Wednesday, March 30th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.03) by $0.33. Phreesia had a negative net margin of 55.41% and a negative return on equity of 25.34%. The firm had revenue of $58.02 million during the quarter, compared to analysts’ expectations of $56.34 million. During the same period in the previous year, the business posted ($0.18) EPS. The business’s revenue was up 38.8% compared to the same quarter last year. Equities analysts expect that Phreesia will post -4.07 EPS for the current year.

In related news, General Counsel Allison C. Hoffman sold 3,909 shares of the company’s stock in a transaction dated Monday, May 9th. The shares were sold at an average price of $17.07, for a total value of $66,726.63. Following the completion of the sale, the general counsel now owns 115,099 shares of the company’s stock, valued at $1,964,739.93. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 5.60% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in PHR. Echo Street Capital Management LLC grew its holdings in shares of Phreesia by 254.5% in the first quarter. Echo Street Capital Management LLC now owns 1,207,228 shares of the company’s stock valued at $31,823,000 after purchasing an additional 866,654 shares during the period. Allspring Global Investments Holdings LLC purchased a new position in Phreesia during the fourth quarter worth about $26,592,000. CI Investments Inc. purchased a new position in Phreesia during the third quarter worth about $22,754,000. Brown Advisory Inc. boosted its stake in Phreesia by 27.4% during the first quarter. Brown Advisory Inc. now owns 1,649,403 shares of the company’s stock worth $43,680,000 after buying an additional 354,378 shares during the period. Finally, BlackRock Inc. boosted its stake in Phreesia by 5.8% during the first quarter. BlackRock Inc. now owns 6,359,641 shares of the company’s stock worth $167,640,000 after buying an additional 349,301 shares during the period. 94.29% of the stock is owned by hedge funds and other institutional investors.

Phreesia Company Profile (Get Rating)

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments.

Featured Articles

Analyst Recommendations for Phreesia (NYSE:PHR)

Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.